AbbVie’s Elezanumab Receives Fast-Track and Orphan Drug Designations for Spinal Cord Injury

The FDA has granted AbbVie’s elezanumab both Fast-Track and Orphan Drug designations for the treatment of patients following spinal cord injury.

Elezanumab is a monoclonal antibody that blocks a molecule which can inhibit neuronal regeneration and functional recovery following central nervous system damage.

AbbVie is currently developing the investigational antibody for the treatment of spinal cord injuries, multiple sclerosis and acute ischemic stroke.